ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. (SPRY) Revenue
Annual & quarterly revenue history · segment & region breakdown
SPRY · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsARS Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.10B, a decrease of 5.46% year-over-year from $0.08B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.08B | -$0.00B | -5.46% |
| 2024-12-31 | $0.09B | +$0.09B | +297063.33% |
| 2023-12-31 | $0.00B | -$0.00B | -97.72% |
| 2022-12-31 | $0.00B | -$0.00B | -76.10% |
| 2021-12-31 | $0.01B | -$0.01B | -69.13% |
| 2020-12-31 | $0.02B | +$0.02B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
Compare revenue vs peers
BiotechnologyCompare SPRY revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ARS Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ARS Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ARS Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
SPRY revenue · 4 questionsSPRY's trailing twelve-month (TTM) revenue is $0.10B. That is a decrease of 5.46% year-over-year from $0.08B in FY2025.
▸ Source: FMP · ARS Pharmaceuticals, Inc. SEC filings · GAAP · ARS Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026